ライフサイエンスコーパス: multimodal therapy

1 ssion to rapid progression despite intensive multimodal therapy.

2 pefully provide more effective, targeted and multimodal therapy.

3 hese men are the most likely to benefit from multimodal therapy.

4 ignancy with a short median survival despite multimodal therapy.

5 tor for poor outcome with current aggressive multimodal therapy.

6 rvival rates less than 40% despite intensive multimodal therapy.

7 have a high likelihood of cure with current multimodal therapy.

8 s and are likely to improve with advances in multimodal therapy.

9 in adults with rhabdomyosarcoma treated with multimodal therapy.

10 -free survival rate in patients who received multimodal therapy.

11 isease, critical for guidance of targeted or multimodal therapy.

12 x, hypopharyngeal tumors, and treatment with multimodal therapy.

13 d 7.71 weeks (95% CI, 6.71-10.14 weeks) with multimodal therapy.

14 ronous metastases, and 402 (73.0%) underwent multimodal therapy.

15 indicator of individual response to evolving multimodal therapies.

16 tients is approximately 14-16 months despite multimodal therapies.

17 Despite multimodal therapy, 5-year overall survival for locally

18 riant of prostate cancer that often warrants multimodal therapy and poses a significant diagnostic ch

19 ions of survival outcomes over time with new multimodal therapies are needed for optimizing treatment

20 atients with rectal cancer who have received multimodal therapy are needed.

21 igh-risk patients are treated with intensive multimodal therapies but cure rates remain suboptimal.

22 gh-risk features; contemporary studies favor multimodal therapy, but high-risk disease is often under

23 Multimodal therapy (chemotherapy, radiation therapy, and

24 apy-naive (or with prior platinum as part of multimodal therapy completed >= 4 months earlier) recurr

25 or progressed within 3-6 months of previous multimodal therapy containing platinum for locally advan

26 Multimodal therapy encompasses a wide range of procedure

27 ring in patients with brain metastases after multimodal therapy, especially in clinical situations wi

28 rature for processes of care and outcomes of multimodal therapies for muscle-invasive urothelial carc

29 their utilization in photomedicine, that is, multimodal therapy for cancer (e.g., PDT, PTT) and antim

30 Therefore, MGH2 provides effective multimodal therapy for gliomas in preclinical models whe

31 radiotherapy is becoming a key component of multimodal therapy for many stages of prostate cancer, p

32 addition, new insights have been gained into multimodal therapy for treating metastatic disease.

33 rm to carry transgenes in order to deliver a multimodal therapy from a single agent.

34 g more effective systemic treatment into the multimodal therapy has been adopted in the CAO/ARO/AIO-0

35 but on assumptions regarding sensitivity to multimodal therapy (i.e., chemotherapy, radiation, intra

36 The use of multimodal therapy improved overall survival in patients

37 Multimodal therapy improves cancer-specific outcomes esp

38 eatment strategies, particularly the role of multimodal therapy in advanced disease.

39 Children with chest wall sarcoma require multimodal therapy including chemotherapy, surgery and/o

40 We conclude that multimodal therapy including extensive PE was associated

41 for 15% of pediatric cancer deaths, despite multimodal therapy including surgical resection.

42 of (18)F-FET PET for treatment monitoring of multimodal therapy, including checkpoint inhibitors, tar

43 enal cell carcinoma should be considered for multimodal therapy, including surgery.

44 ed therapy, in the current era of sequential multimodal therapy incorporating novel treatments.

45 f patients with oral cavity cancer requiring multimodal therapy, initiation of radiation therapy with

46 cell carcinoma (HNSCC) patients that require multimodal therapy involving chemotherapy in conjunction

47 Multimodal therapy is a well-established approach for th

48 Multimodal therapy is composed of chemotherapy and surgi

49 Multimodal therapy is generally more effective than sing

50 , class III clinical trials demonstrate that multimodal therapy is important for both life quality an

51 Alternatively, multimodal therapy is increasingly recognized as a criti

52 Multimodal therapy is increasingly the standard of care

53 DSRCT have not been developed, and standard multimodal therapy is insufficient, leading to a 5-year

54 Sarcopenia increases through multimodal therapy, is associated with an increased risk

55 oscale drug delivery vehicles can facilitate multimodal therapies of cancer by promoting tumour-selec

56 est incorporation of this agent into initial multimodal therapy of neuroblastoma.

57 to explore factors associated with need for multimodal therapy on AS relapse.

58 nt was defined as RP with appropriate use of multimodal therapy (optimal RP), EBRT with at least 2 ye

59 All patients undergoing multimodal therapy or surgery with curative intent from

60 Despite multimodal therapy, outcome in rhabdoid tumours remains

61 Despite such aggressive multimodal therapy, prognosis remains poor, with a media

62 ogic features receiving guideline-concordant multimodal therapy, prostate cancer-specific mortality o

63 ly addition to a waiting list and aggressive multimodal therapy provide excellent results.

64 Patients were treated with risk-directed multimodal therapy regardless of race, ethnicity, or abi

65 nly about one third of patients treated with multimodal therapy remain disease-free, and local contro

66 dence of SNs was higher among survivors with multimodal therapy (standard risk, 9.5%; historical, 2.8

67 Multimodal therapy strategies have improved patients' su

68 On multivariate analysis, the use of multimodal therapy strategies was significantly associat

69 xclusive psychological treatment rather than multimodal therapies, substantially limiting rehabilitat

70 ) patients including 255 patients undergoing multimodal therapy (surgery with chemotherapy, radiation

71 Despite intensive multimodal therapy (surgery, chemotherapy and, if age pe

72 s will all be required to accommodate PAT, a multimodal therapy that combines pharmacological and psy

73 usion: Given the considerable annual cost of multimodal therapy, the integration of (18)F-FET PET can

74 Despite the use of intensive contemporary multimodal therapy, the overall survival of patients wit

75 he osteoclast and osteoblast compartments as multimodal therapy to prevent SBD.

76 lthough there have been recent advances with multimodal therapy, treatment of neuroblastoma remains a

77 total of 393 consecutive patients completing multimodal therapy were studied, all with prospectively

78 ed nanoplatforms that embrace the concept of multimodal therapy, which aims to combine MHT with chemo

79 Pioneered by the Mayo Clinic, multimodal therapy with neoadjuvant chemoradiotherapy an

80 inoma, there is a focus on local control and multimodal therapy with radiation.

81 tandard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk n

82 Although advances in multimodal therapy yielded a 5-year survivorship of 80%,